The global companion diagnostics (CDx) development market reached USD 845.99 million in 2024 and is forecast to grow at a CAGR of 7.6% through 2034, reflecting the field’s entrenched position in modern drug development and personalized medicine. While the United States remains the dominant market globally, countries such as China, Germany, and South Korea are playing pivotal roles in shaping the industry’s trajectory. National policy impact, market share concentration, R&D leadership, and strategic positioning are increasingly influential in determining corporate success amid rising global competition and shifting geopolit